angiotensin ii has been researched along with sacubitril in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, H; AlSiraj, Y; Cassis, LA; Ensor, M; Liang, CL; Thatcher, SE | 1 |
| Li, CY; Li, SN; Xi, H; Zhang, JR; Zhao, L; Zhou, L | 1 |
2 other study(ies) available for angiotensin ii and sacubitril
| Article | Year |
|---|---|
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Topics: Aminobutyrates; Angiotensin II; Animals; Antihypertensive Agents; Atherosclerosis; Biphenyl Compounds; Mice; Neprilysin | 2021 |
Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
Topics: Aminobutyrates; Angiotensin II; Animals; Atrial Fibrillation; Biphenyl Compounds; Fibrosis; Rats; Signal Transduction; Valsartan | 2022 |